Tags : Pracinostat

Helsinn and MEI Terminate its P-III Study of Pracinostat for

Shots: Interim analysis of the ongoing P-III study of pracinostat + azacitidine in patients with AML who are unfit to receive CT demonstrated that it was unlikely to meet its 1EPs of OS Based on the outcome of the interim analysis, the companies will discontinue the ongoing study as the decision is based on a […]Read More

Helsinn Enters into an Exclusive Distribution and License Agreement with

Shots: Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, and Uruguay. Helsinn to retain rights all international developments including clinical activities & supply of Pracinostat In 2016, MEI Pharma granted global rights of Pracinostat to Helsinn and a right to […]Read More